What Anucort-HC Treats: Main Uses and Benefits

Anucort-HC is considered relevant for managing conditions characterized by inflammatory or irritative processes in the anorectum, used primarily when short-term supportive symptom management is appropriate for localized discomfort. The medication is utilized for therapeutic management involving distressing symptoms associated with inflamed hemorrhoids, ulcerative proctitis, cryptitis, and post-irradiation (factitial) proctitis.

It is primarily used to address symptom clusters that may appear suddenly or intensify over time, such as severe rectal pain, noticeable tissue swelling, and persistent pruritus ani (anal itching). This support assists with maintaining functional stability by helping patients cope more steadily with symptom fluctuations.

“The primary goal is to provide supportive relief during episodes of heightened discomfort by addressing the symptoms related to inflammatory or irritative states.”

It is commonly used when symptoms intensify and supportive relief is needed, and may be part of symptomatic management applied in scenarios where additional management of discomfort is required, especially in conditions characterized by recurrent or episodic manifestations.

---

Quick Fact: Relief for Inflammatory Symptoms Anucort-HC is relevant for conditions presenting with symptoms of heightened discomfort, such as localized pain, swelling, and itching, and may assist with managing symptoms that interfere with daily functioning during symptomatic flares.

Regulatory References

1. DailyMed (NIH) drug label for Hydrocortisone Acetate Suppositories

Official Eligibility Rules for Anucort-HC

Eligibility for Anucort-HC (Hydrocortisone Acetate Rectal Suppository) is strictly defined by regulatory documents, focusing on patient history, age, and concurrent health conditions. It is contraindicated for individuals with a history of hypersensitivity to hydrocortisone acetate or any of the product's components. Additionally, the medicine must not be used in the presence of local tubercular, fungal, or viral lesions, including herpes simplex, in the treatment area.

---

Restricted and Conditional Use

Population Group	Regulatory Status
Pediatric Patients (Under 18)	Use is not established; many regulatory profiles state use is not recommended for this age group.
Pregnancy	Designated as Category C. Use is strongly restricted and is not recommended for extensive or prolonged periods.
Lactation	Excretion into human milk is unknown. A decision to discontinue nursing or discontinue the drug is required due to the potential for infant adverse reactions.
Active Infection	Conditional use; treatment must be discontinued if a co-existing anorectal infection is not quickly controlled by an appropriate anti-infective agent.

---

Use of this medicine is generally established for the adult population and is conditional upon having an adequate proctologic examination performed prior to or during treatment. Prolonged or excessive use is not recommended by regulators.

Interactions with other medicines and products

The official regulatory profile for Hydrocortisone Acetate Rectal Suppositories (the active component of Anucort-HC) is primarily defined by the absence of specific, formally documented interaction patterns in the government-approved prescribing information. This status is consistent with the drug’s local route of administration, which results in limited systemic absorption of the corticosteroid into the bloodstream, thereby reducing the likelihood of systemic pharmacokinetic interactions.

Interaction Category	Regulatory Documentation Status
Formally Listed Interacting Agents	None specifically listed in the regulatory interaction profile.
Documented Metabolic/Enzyme Effects	None formally documented (e.g., CYP-mediated effects or transporter interactions).
Contraindicated Combinations	None formally documented in the interaction profile.
Timing-Separation Rules	None mandated due to documented interaction risk.
Food, Alcohol, or Supplement Interactions	None formally documented.

The official labeling does not describe mandatory co-administration separation rules, prohibit specific combinations, or list substances that are documented to alter drug exposure through metabolic or transport mechanisms. Consequently, the regulatory document does not formally classify any specific drug-drug interaction for this formulation as Contraindicated, Major, or Moderate risk. The interaction profile strictly reflects the information, or absence of information, explicitly stated within the official government prescribing documents for the rectal suppository formulation.

Anucort-HC contains hydrocortisone acetate, a corticosteroid delivered locally to the anorectal mucosa. The active moiety, hydrocortisone, functions as an agonist at the intracellular glucocorticoid receptor (GR) within targeted cells. Upon ligand binding, the activated GR complex translocates to the nucleus, where it modulates gene transcription through two primary mechanisms: transactivation and transrepression.

Transrepression involves the inhibition of pro-inflammatory transcription factors, such as NF-kappaB and AP-1. This action decreases the transcription of genes encoding various pro-inflammatory mediators, including cytokines, chemokines, and inducible enzymes like cyclooxygenase-2 (COX-2) and phospholipase A2 (PLA2). The decreased expression of PLA2 restricts the release of arachidonic acid, thereby limiting the downstream synthesis of eicosanoids (prostaglandins and leukotrienes).

Separately, hydrocortisone induces the synthesis of Annexin A1 (formerly Lipocortin-1), a protein that directly inhibits PLA2 activity. These actions collectively suppress the molecular cascade of inflammation. At the system level, this pharmacodynamic modulation leads to localized microvascular vasoconstriction and a reduction in capillary permeability and leukocyte migration into the affected tissue.

The official use of Anucort-HC is strictly defined by its presentation as a 25 mg rectal suppository, intended exclusively for localized rectal administration. Adherence to the official labeled instructions ensures the medicine is used according to its designed delivery method and established temporal boundaries.

Prior to commencing use, the official labeling requires that an adequate proctologic examination has been conducted, establishing a necessary prerequisite for administration.

Administration Principle	Labeled Instruction Summary
Standard Dosing	One suppository (25 mg) per administration, twice daily (morning and night).
Higher Dosing	For severe cases: one suppository three times daily or two suppositories twice daily.

The duration of administration is time-bound and based on the specific condition. For nonspecific proctitis, the course is typically limited to two weeks. When used for factitial proctitis, the official course may extend up to six to eight weeks or less, contingent upon the individual's response.

Proper administration involves gentle insertion of the suppository with the pointed end first. Patients are instructed to avoid excessive handling, as the formulation is designed to melt quickly at body temperature. If an administration is forgotten, the procedural guideline is to insert the dose when remembered unless it is nearly time for the next scheduled administration, in which case the missed dose should be omitted.

Research Evidence / Overview of Studies for Anucort-HC

---

Evidence for Symptomatic Internal Hemorrhoids and Ulcerative Proctitis

Research has explored the medicine's use in symptomatic internal hemorrhoids through short-term, randomized, vehicle-controlled trials. These studies primarily examined outcomes related to physical discomfort, such as patient-reported scores for pain, itching, and the monitoring of anorectal bleeding. For active ulcerative proctitis (inflammation limited to the rectum), the evidence includes Phase 3 Randomized Controlled Trials (RCTs) that compared the suppository to a placebo. These trials focused on the achievement of Clinical Remission, defined by composite scores including endoscopic findings and patient-reported symptoms. Study reports describe patterns observed during the initial short-term treatment phases.

---

Evidence for Other Conditions and Specific Subgroups

The research base for other conditions involving inflammatory or irritative states—such as post-irradiation (factitial) proctitis—is primarily supported by historical data and observational evidence. This often relies on extrapolation from studies of other topical steroid forms. Uncertainty remains for these specific indications, as large-scale, dedicated placebo-controlled trials for the suppository formulation are limited.

Furthermore, data for certain groups, such as children or those with extensive comorbidities, remain insufficient in the core regulatory documentation. Findings describe group patterns, but the research provides limited specific information for certain subgroups where dedicated data are lacking.

---

Research Gaps and Follow-up Limitations

The vast majority of research focuses on short-term changes over defined intervals, such as courses lasting three to four weeks. Follow-up durations were limited in most core studies, meaning there is limited information for long-term outcomes or how durable the observed patterns might be. Consequently, long-term effects are not fully established. Comparative evidence is also limited in some areas, as there are few published studies that directly compare the suppository against other active prescription treatments.

Common questions about Anucort-HC (FAQ)

---

Q: Is Anucort-HC the same as hydrocortisone cream I can buy over the counter?

Anucort-HC is a prescription-only product. It is a rectal suppository that delivers a 25 mg dose of hydrocortisone acetate, intended for specific localized use inside the anal canal or lower rectum. In contrast, over-the-counter hydrocortisone creams have different strengths, a cream form, and are formulated for external topical skin use.

---

Q: What does the 'HC' part of the name Anucort-HC stand for?

The active ingredient in the medicine is Hydrocortisone Acetate. The 'HC' typically refers to the common medical abbreviation for the corticosteroid HydroCortisone. This is a synthetic version of the naturally occurring hormone cortisol.

---

Q: Can Anucort-HC cause skin irritation or burning?

Official regulatory documents list local adverse reactions that can occur at the site of application. These commonly reported reactions include sensations such as burning, itching, and irritation.

---

Q: Is it possible to experience side effects like thinning skin from using Anucort-HC?

Changes to the skin, including thinning or lightening (hypopigmentation), are known potential effects of the corticosteroid class of medicines. This potential is generally noted to increase when corticosteroids are used for prolonged durations or extensively.

---

Q: What signs might indicate someone is having a reaction to Anucort-HC?

The official labeling indicates that if excessive irritation develops or a secondary infection is not controlled by an appropriate anti-infective agent, the medicine is described as being discontinued.

---

Q: What should be done if someone accidentally uses more Anucort-HC than described in official instructions?

The labeling advises that if signs of systemic overdosage occur, the medication is generally discontinued under medical observation. General safety information notes that all drugs should be kept out of the reach of children and advises contacting a Poison Control Center immediately following accidental ingestion.

---

Q: What is the difference between Anucort-HC and over-the-counter hydrocortisone products in terms of strength?

The Anucort-HC suppository is supplied as a 25 mg dose of hydrocortisone acetate. The 25 mg dose of hydrocortisone acetate in the suppository form is typically a different concentration than the lower strengths found in over-the-counter hydrocortisone products designed for external use.

---

Q: What happens if a person uses Anucort-HC and they also have diabetes?

Corticosteroids are generally known to affect glucose metabolism. While systemic absorption is limited, the potential for systemic effects means this information is relevant for individuals managing blood sugar levels.

---

Q: Why is Anucort-HC available only by prescription?

The medicine is classified as prescription-only due to the potency of the corticosteroid ingredient. Furthermore, the official labeling describes the necessity of an adequate proctologic examination prior to use, which is a regulatory prerequisite for administration.

---

Q: What are the most common reasons a doctor prescribes Anucort-HC?

The medication is officially indicated for managing localized inflammation and swelling. This includes the symptoms associated with conditions such as ulcerative proctitis, factitial proctitis (inflammation after radiation), and certain cases of symptomatic internal hemorrhoids.

---

Q: Can Anucort-HC affect the results of any blood tests?

If the active ingredient is absorbed systemically, it may cause reversible suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Specialized tests that monitor adrenal function may detect this effect, especially during prolonged or extensive treatment.

---

Q: Are there any medications that interact with Anucort-HC?

The official regulatory profile for this suppository formulation is primarily defined by the absence of specific, formally documented interaction patterns in government-approved prescribing information.

---

Q: Does Anucort-HC interact with common pain relievers like ibuprofen or aspirin?

The official regulatory documents do not list specific interactions with common over-the-counter pain relievers such as ibuprofen or aspirin.

---

Q: Are there any specific supplements or herbal products that should be mentioned to a doctor before using Anucort-HC?

The regulatory document does not formally classify any specific food or supplement interaction for this medicine. The regulatory document emphasizes informing a health professional of all products being used.

---

Q: Is Anucort-HC approved for use in children?

The regulatory documentation states that the use of this medicine in pediatric patients (those under 18 years of age) is not established and is not advised for this age group.

---

Q: What conditions would make a person ineligible to use Anucort-HC?

The medicine is contraindicated (not to be used) in people with a history of hypersensitivity to any component of the suppository. It must also be avoided if local tubercular, fungal, or viral lesions, such as herpes simplex, are present in the treatment area.

---

Q: Does Anucort-HC treat the cause of the issue or just the symptoms?

The drug's mechanism of action is primarily to function as a powerful local anti-inflammatory and anti-pruritic (anti-itching) agent. Its main purpose is to suppress the inflammatory cascade and mitigate the associated symptoms, providing relief from discomfort and swelling.

---

Q: Is Anucort-HC known to cause drowsiness?

Official regulatory documentation does not list drowsiness among the commonly reported local or systemic adverse reactions for this product.

---

Q: Are there specific food items or drinks that need to be avoided while using Anucort-HC?

The regulatory document does not formally classify any specific food, dietary, or alcohol interaction for this rectal suppository formulation.

---

Q: Does Anucort-HC contain any local anesthetics?

The active ingredient in the suppository is Hydrocortisone Acetate. The official product description does not list a local anesthetic as an active component in this specific formulation.

---

Q: Is Anucort-HC habit-forming or associated with withdrawal effects?

The medicine is not typically described as 'habit-forming.' However, prolonged or extensive use can lead to HPA axis suppression. If this suppression occurs, the official labeling indicates the medicine is generally discontinued and managed under medical observation.

---

Q: Can Anucort-HC be used if someone has an allergy to sulfa drugs?

Contraindications for this medicine are limited to hypersensitivity to hydrocortisone acetate or any of its components. The official description of the components does not list sulfa-containing drugs in the formulation.

---

Q: Do any official documents discuss the potential for Anucort-HC to mask symptoms of a more serious issue?

The official labeling requires an adequate proctologic examination to be conducted prior to the start of treatment. This prerequisite is established to rule out the possibility of more serious pathology prior to use.

---

Q: Can Anucort-HC be used by someone who is taking blood thinners?

The regulatory profile for this specific suppository formulation does not formally classify any specific interaction with blood thinners (anticoagulants).

---

Q: What kind of patient populations are usually excluded from Anucort-HC use in clinical studies?

Official research reports indicate that dedicated clinical data is often insufficient or limited for certain groups. These typically include pediatric patients and those with extensive or serious pre-existing comorbidities.

---

Q: Does Anucort-HC have an expiry date that is important to follow?

Yes. The suppository's stability is maintained until the labeled expiration date, provided it is stored correctly at the mandated controlled room temperature and protected from heat or freezing.

---

Q: Can Anucort-HC cause headaches or dizziness in some people?

Official regulatory documentation does not list headaches or dizziness among the commonly reported local or systemic adverse reactions for this product.

Storage and Disposal of Anucort-HC

The official labeling for Anucort-HC (hydrocortisone acetate suppository) sets mandatory conditions to ensure product integrity and public safety.

---

Required Storage and Handling

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F), with excursions permitted up to 30 C (86 F).
Environmental Protection	Must be protected from freezing and stored away from heat. The suppository's low melting point requires temperature control.
Child Safety	Keep this and all drugs out of the reach of children. In case of accidental ingestion, immediately contact a Poison Control Center.

---

Official Disposal Instructions

Disposal instructions in regulatory documents require that any unused or expired Anucort-HC and related waste material be disposed of in accordance with local requirements for medicinal products. The suppository's stability is maintained until the labeled expiration date, provided it is stored within the mandated temperature range.